Madrid, 23-27 October 2026
Members of the SAGITTARIUS consortium participated in the ESMO Congress 2026, one of the world’s leading scientific meetings in oncology. The event, held in Madrid, Spain, brought together researchers, clinicians and cancer experts from across the globe to discuss the latest advances in cancer research, diagnosis and treatment.
As part of the congress programme, researchers involved in SAGITTARIUS presented three scientific posters showcasing preliminary findings from the trial. Moreover, a digital poster illustrated preliminary results about the SAGITTARIUS approach cost-effectiveness.
The posters
On 23 October, Luca Lazzari (IFOM) presented poster 4265P in the Translational Research and Biomarkers track, “Genomic alterations and association with post-surgery circulating tumor DNA status in early-stage colon cancer”. On the 25 October, within the Colon Cancer session, Vicente Alonso-Orduña and Stefano Tamberi presented posters 808P and 810P, respectively:
- “Post-surgery ctDNA negativity influences adjuvant treatment decisions in colon cancer: a paired counterfactual analysis from the SAGITTARIUS trial”;
- “ctDNA-guided adjuvant trials in colon cancer may miss the molecular residual disease (MRD) window: evidence of early attrition during trial allocation”.
The first author of the e-poster, 870eP “Cost-effectiveness of a dynamic ctDNA-guided adjuvant strategy in stage II–III colon cancer. A SAGITTARIUS model-based analysis”, was Carlo Federici (Bocconi University).
Although the findings remain preliminary and will be further analysed and expanded as the project progresses, the posters attracted considerable attention from congress participants. Researchers, clinicians and industry representatives visited the poster sessions, engaged in discussions with the presenters and asked numerous questions about the study design, methodology and potential clinical implications of the SAGITTARIUS approach.
The strong interest shown by the oncology community highlights the relevance of the project’s objectives and the growing importance of liquid biopsy and ctDNA-guided strategies in supporting more personalised treatment decisions for patients with cancer.
The consortium looks forward to further developing these analyses and sharing additional results from SAGITTARIUS in future scientific meetings and publications.
More about SAGITTARIUS
For further information on the SAGITTARIUS project or to participate in its trial, please contact clinical.trials@ifom.eu.
To learn more:
- Media contact: info@sagittarius-horizon.eu
- Social media: LinkedIn, Facebook, X, Instagram, YouTube
- Subscribe to the SAGITTARIUS newsletter
